NVIDIA and Eli Lilly announced a five‑year, $1 billion co‑innovation lab to deploy large‑scale AI computing and models for drug discovery, signaling a major industry pivot to tightly integrated hardware‑software partnerships. The initiative will leverage NVIDIA’s BioNeMo and related AI stacks with Lilly’s drug‑discovery assets to accelerate in‑silico chemistry and biology workflows. Separately, Thermo Fisher struck a strategic collaboration with NVIDIA to integrate AI into scientific instruments and lab workflows, aiming to automate experiments and accelerate data‑to‑insight cycles. Both deals underscore a surge in partnerships that pair cloud and accelerator firms with life sciences incumbents to operationalize AI across discovery and translational stages.